Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MNCs Urge Indonesia For Exemption From Decree Requiring Local Manufacturing Facilities

This article was originally published in PharmAsia News

Executive Summary

Multinational companies are putting pressure on Indonesia's Ministry of Health to exempt them from a new decree requiring foreign drug companies to have local production facilities or leave Indonesia, according to Merck and Sanofi-Aventis

You may also be interested in...



Not Enough Beds To Go Around To Meet Asia’s Rising Demand For Medical Tourism

Frost & Sullivan weighs in on the state of medical tourism in southeast Asia, where some countries see greater opportunities for public-private partnerships.

Korean Government Fines Five Pharma Multinationals For Unfair Trade

SEOUL - South Korea's trade watchdog, the Fair Trade Commission, has imposed fines collectively totaling KRW 20.48 billion ($14.8 million) on seven pharmaceutical companies - including five multinationals - on charges of unfair provision of rebates and other improper benefits to doctors and hospitals

Korean Government Fines Five Pharma Multinationals For Unfair Trade

SEOUL - South Korea's trade watchdog, the Fair Trade Commission, has imposed fines collectively totaling KRW 20.48 billion ($14.8 million) on seven pharmaceutical companies - including five multinationals - on charges of unfair provision of rebates and other improper benefits to doctors and hospitals

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel